View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offer...

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field BioNTech has completed its exchange offer to acquire CureVacAcquisition complements BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturingIn total, approximately 86.75% of CureVac shares were tendered; BioNTech expects to complete the compulsory acquisition of the remaining CureVac shares in January 2026 as part of the previously announced post-offer reorganizationCureVac will continue to operate unde...

 PRESS RELEASE

BioNTech schließt Übernahme von CureVac N.V. samt damit verbundener Na...

BioNTech schließt Übernahme von CureVac N.V. samt damit verbundener Nachangebotsfrist ab und stärkt so die einzigartige Position im mRNA-Feld BioNTech hat das Umtauschangebot zur Übernahme von CureVac abgeschlossenDie Übernahme von CureVac ergänzt BioNTechs Fähigkeiten und unternehmenseigene Technologien im Bereich mRNA-Design, Verabreichungsformulierungen und mRNA-HerstellungInsgesamt wurden etwa 86,75 Prozent der CureVac-Aktien angedient; BioNTech geht davon aus, dass der obligatorische Erwerb der verbleibenden CureVac-Aktien im Januar 2026 im Rahmen der zuvor angekündigten Nach-Angebots-...

 PRESS RELEASE

Euronext announces December 2025 quarterly review results of the PSI®

Euronext announces December 2025 quarterly review results of the PSI® Lisbon – 10 December 2025 Euronext today announced the results of the annual review for the PSI®, which will be implemented after markets close on Friday 19 December 2025 and will be effective from Monday 22 December 2025. Results of the December 2025 quarterly review PSI® No changes in the composition of the index The Independent Supervisor retains the right to change the published selection, for instance in the case of a removal due to a takeover, until the publication of the final data after close of Wednesday 17 ...

 PRESS RELEASE

Erste Ergebnisse aus BioNTechs und BMS’ globaler Phase-2-Studie mit bi...

Erste Ergebnisse aus BioNTechs und BMS’ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig zeigten ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem dreifach negativem Brustkrebs Zwischenergebnisse der globalen klinischen Phase-2-Studie bei lokal fortgeschrittenem/metastasiertem dreifach negativem Brustkrebs (triple-negative breast cancer, „TNBC“) zeigten eine ermutigende Anti-Tumor-Aktivität für Pumitamig (BNT327/BMS986545) in Kombination mit Chemotherapie bei Patientinnen und Patienten in der Erst- oder ZweitlinienbehandlungPumitamig in Kombination m...

 PRESS RELEASE

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data fo...

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first- and second-line patientsPumitamig plus chemotherapy achieved confirmed objective response rate (cORR) of 61.5%, unconfirmed ORR (uORR) of 71.8% and disease control rate (DCR) of 92.3% irrespec...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ageas: Finally, 100% owner of Belgium business. CTP: Official launch in Italy and expansion in CTPark Warsaw South. Euronext: November delivers positive cash equity and bond trading volume growth. IBA: IBA to install one P1 system at YAS Healthcare in Dubai

 PRESS RELEASE

BioNTechs und OncoC4s selektiver Treg-Modulatorkandidat Gotistobart er...

BioNTechs und OncoC4s selektiver Treg-Modulatorkandidat Gotistobart erzielte klinisch relevanten Gesamtüberlebensvorteil bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge Der selektive Treg-Modulatorkandidat Gotistobart (BNT316/ONC-392) zeigte eine Verringerung des Sterberisikos um mehr als die Hälfte im Vergleich zur Standard-Chemotherapie sowie ein kontrollierbares Sicherheitsprofil im ersten von zwei Abschnitten der globalen, klinischen Phase-3-Studie PRESERVE-003 bei Patientinnen und Patienten mit Plattenepithelkarzinom der Lunge (squamous non-small c...

 PRESS RELEASE

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Be...

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the first of two stages of the global Phase 3 trial PRESERVE-003 in patients with squamous non-small cell lung cancer (“sqNSCLC”) who have progressed on prior immunotherapy plus chemotherapyMedian OS with gotistobart ha...

 PRESS RELEASE

Euronext announces volumes for November 2025

Euronext announces volumes for November 2025 Euronext announces volumes for November 2025 Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 5 December 2025 – Euronext, the leading European capital market infrastructure, today announced trading volumes for November 2025. Monthly and historical volume tables are available at this address: CONTACTS   ANALYSTS & INVESTORS – Investor Relations        Judith Stein         97         Margaux Kurver         03         MEDIA –   Europe        Andrea Monzani          13          Sandra Machado         7 Belgium      ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch